EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Dynamic monitoring of antibody drug conjugates targeting TROP2 or HER2 in breast cancer using circulating tumor cells

Avanish Mishra, Rachel O Abelman, Quinn Cunneely, Victor Putaturo, Akansha A Deshpande, Remy Bell, Elizabeth M Seider, Katherine H Xu, Mythreayi Shan, Justin Kelly, Shih-Bo Huang, Olivia Rieur und 13 weitere

Proceedings of the National Academy of Sciences · 23.06.2026 · 123 (25)

DOI: 10.1073/pnas.2601563123 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 17.06.2026. Verfasst von Avanish Mishra und 24 weiteren Autor:innen. Beteiligte Einrichtung: Center for Engineering in Medicine and Surgery, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129. Hauptthemen laut MEDLINE: Neoplastic Cells, Circulating, Cell Adhesion Molecules, Antigens, Neoplasm, Breast Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: HHS | NIH | National Cancer Institute (NCI), Breast Cancer Research Foundation (BCRF), NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antibody–drug conjugates (ADCs) target surface proteins on cancer cells, leading to internalization and delivery of a drug payload, thereby enhancing selectivity and minimizing toxicity. ADCs against TROP2 (Sacituzumab govitecan) or HER2 (T-DXd) have demonstrated efficacy in metastatic breast cancer, yet paradoxically, outside of HER2 -amplified breast cancers, expression levels of these breast cancer-enriched epitopes in tumor biopsies have not been strongly correlated with clinical response. We undertook serial quantitative imaging of circulating tumor cells (CTCs) in a prospective cohort of 35 patients treated with either of these ADCs. At the single-cell level, expression of TROP2 and HER2 within individual patients is highly heterogeneous in both CTCs and paired tumor biopsies. Measurement of these epitopes on CTCs immediately prior to ADC therapy does not predict depth of clinical response. However, absence of CTCs or >80% reduction in CTC numbers after three weeks of treatment (CTC Low ) predicts durable response, compared with CTC High cases (TROP2: HR 5.15, P = 0.012; HER2: HR 6.01, P < 0.001). Targeted epitopes are not commonly downregulated on CTCs at the time of acquired clinical resistance, and switching between TROP2- and HER2-targeting ADCs sharing similar payloads infrequently leads to second-line response. Thus, while CTC burden is correlated with response to these ADCs, the level of TROP2 or HER2 expression is poorly predictive. These findings point to sensitivity to the drug payload as a potential driver of clinical response to currently approved ADCs in breast cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neoplastic Cells, CirculatingCell Adhesion MoleculesAntigens, NeoplasmBreast NeoplasmsErb-b2 Receptor Tyrosine KinasesImmunoconjugatesAntibodies, Monoclonal, HumanizedHumansFemaleProspective StudiesCamptothecin

Stichwörter der Autor:innen

HER2TROP2antibody-drug-conjugatebreast cancercirculating tumor cells

Substanzen

Cell Adhesion MoleculesAntigens, NeoplasmTACSTD2 protein, humanErb-b2 Receptor Tyrosine KinasesImmunoconjugatesERBB2 protein, humansacituzumab govitecanAntibodies, Monoclonal, HumanizedCamptothecin

Autor:innen und Institutionen

  • Center for Engineering in Medicine and Surgery, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129.
  • Krantz Family Center for Cancer Research, Massachusetts General Hospital Cancer Center and Harvard Medical School, Charlestown, MA 02129.
  • Division of Hematology Oncology, Massachusetts General Hospital Cancer Center and Department of Medicine, Harvard Medical School, Boston, MA 02114.
  • Howard Hughes Medical Institute, Chevy Chase, MD 20815.
  • Shriners Children's Hospital Boston, MA 02114.

ORCID-Profile: Leif W Ellisen, David T Ting, Daniel A Haber

Förderung

  • HHS | NIH | National Cancer Institute (NCI)
  • Breast Cancer Research Foundation (BCRF)
  • NHLBI NIH HHS
  • Howard Hughes Medical Institute (HHMI)
  • National Foundation for Cancer Research (NFCR)
  • NCI NIH HHS

Zitieren

APA

Mishra, A., Abelman, R. O., Cunneely, Q., Putaturo, V., Deshpande, A. A., Bell, R., Seider, E. M., Xu, K. H., Shan, M., Kelly, J., Huang, S. B., Rieur, O., Knape, J., Gopinathan, K. A., Kikkeri, K., Edd, J. F., Walsh, J., Dai, C. S., Ellisen, L. W., …, & Maheswaran, S. (2026). Dynamic monitoring of antibody drug conjugates targeting TROP2 or HER2 in breast cancer using circulating tumor cells. Proceedings of the National Academy of Sciences, 123(25). https://doi.org/10.1073/pnas.2601563123

Vancouver

Mishra A, Abelman RO, Cunneely Q, Putaturo V, Deshpande AA, Bell R, et al. Dynamic monitoring of antibody drug conjugates targeting TROP2 or HER2 in breast cancer using circulating tumor cells. Proceedings of the National Academy of Sciences. 2026;123(25). doi:10.1073/pnas.2601563123

BibTeX
@article{Mishra2026,
  author = {Mishra, Avanish and Abelman, Rachel O and Cunneely, Quinn and Putaturo, Victor and Deshpande, Akansha A and Bell, Remy and Seider, Elizabeth M and Xu, Katherine H and Shan, Mythreayi and Kelly, Justin and Huang, Shih-Bo and Rieur, Olivia and Knape, Justine and Gopinathan, Kaustav A and Kikkeri, Kruthika and Edd, Jon F and Walsh, John and Dai, Charles S and Ellisen, Leif W and Ting, David T and Nieman, Linda and Toner, Mehmet and Bardia, Aditya and Haber, Daniel A and Maheswaran, Shyamala},
  title = {Dynamic monitoring of antibody drug conjugates targeting TROP2 or HER2 in breast cancer using circulating tumor cells},
  journal = {Proceedings of the National Academy of Sciences},
  year = {2026},
  volume = {123},
  number = {25},
  doi = {10.1073/pnas.2601563123}
}
Kostenlos starten →